Bubs Australia has reported a strong Q2 FY25 performance with a positive EBITDA turnaround and robust revenue growth, while advancing its critical FDA clinical trial in the US.
Fonterra Shareholders' Fund has secured conditional approval to delist from the ASX, aiming to consolidate its trading on the NZX by late February 2025. This move is expected to streamline operations and reduce costs for unitholders.
